Top Markets
#1 TENDIES TENDIES +42.62%
#2 Cash Cat Cash Cat +27.92%
#3 ICON ICON +23.59%
#4 Asteroid Shiba Asteroid Shiba +17.29%
#5 OSK OSK +15.36%
#6 MarsCoin MarsCoin +13.78%
#7 Threshold Network Threshold Network +12.29%
#8 龙虾 (Lobster) 龙虾 (Lobster) +10.00%
#9 Tornado Cash Tornado Cash +9.69%
#10 Kite Kite +9.57%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Rank in Stocks #16730
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Share Price
$3.78
Last synced: 2026-03-17
Market Cap
$276.54M
Change (1 day)
0.00%
Change (1 year)
45.53%
Country
CA
Trade NervGen Pharma Corp. (NGEN)

Category

Healthcare
Revenue for NervGen Pharma Corp. (NGEN)
Revenue in Sep 2026 TTM: 0
According to NervGen Pharma Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for NervGen Pharma Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH